CombinatoRx inks $62M collaboration with Novartis

CombinatoRx nailed a $4 million upfront payment from Novartis for a new oncology collaboration. "The collaboration will explore combination effects in cell lines representing a broad spectrum of cancers to provide a robust and systematic understanding of combination therapy opportunities," said the company, which also stands to earn up to $58 million in milestones. Report